CF PharmTech, Inc. (HKG:2652)
Hong Kong · Delayed Price · Currency is HKD 6.06
+0.31 (5.30%)
Oct 9, 2026, 4:08 PM HKT
CF PharmTech Revenue
CF PharmTech had revenue of 105.08M CNY in the quarter ending June 30, 2026, a decrease of -24.82%. This brings the company's revenue in the last twelve months to 436.80M, down -28.13% year-over-year. In the year 2025, CF PharmTech had annual revenue of 432.52M, down -28.83%. That makes CF PharmTech the 26,042nd largest company in the world by revenue and 1,544th in Hong Kong.
Revenue (ttm)
436.80M CNY
Revenue Growth
-28.13%
P/S Ratio
4.88
Revenue / Employee
698.87K CNY
Employees
625
Market Cap
2.46B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 432.52M | -175.23M | -28.83% |
| Dec 31, 2024 | 607.75M | 51.33M | 9.23% |
| Dec 31, 2023 | 556.42M | 207.29M | 59.37% |
| Dec 31, 2022 | 349.13M | 307.14M | 731.54% |
| Dec 31, 2021 | 41.99M | 37.13M | 764.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CPBIO Holding Company | 3.32B |
| Edding Genor Group Holdings | 2.57B |
| Essex Bio-Technology | 1.72B |
| Jacobson Pharma Corporation | 1.57B |
| Dawnrays Pharmaceutical (Holdings) | 1.32B |
| Golden Throat Holdings Group Company | 1.04B |
| Jilin Province Huinan Changlong Bio-pharmacy Company | 1.04B |
| JBM (Healthcare) | 834.63M |